Elemer Piros analyst

Currently out of the existing stock ratings of Elemer Piros, 197 are a BUY (84.55%), 20 are a HOLD (8.58%), 16 are a SELL (6.87%).

Elemer Piros

Work Performance Price Targets & Ratings Chart

Analyst Elemer Piros, carries an average stock price target met ratio of 34.89% that have a potential upside of 61.79% achieved within 234 days. Previously, Elemer Piros worked at BENCHMARK.

Elemer Piros’s has documented 456 price targets and ratings displayed on 51 stocks. The coverage was on Healthcare, Industrials sectors.

Most recent stock forecast was given on INMB, INmune Bio at 11-Mar-2026.

Wall Street Analyst Elemer Piros

Analyst best performing recommendations are on ARCT (ARCTURUS THERAPEUTICS HOLDINGS).
The best stock recommendation documented was for ARCT (ARCTURUS THERAPEUTICS HOLDINGS) at 3/2/2021. The price target of $45 was fulfilled within 3 days with a profit of $8.96 (16.6%) receiving and performance score of 55.35.

Average potential price target upside

ABEO Abeona Therapeutics AERI Aerie Pharmaceuticals APLS Apellis Pharmaceuticals ARWR Arrowhead Pharmaceuticals BLUE Bluebird bio CMPS Compass Pathways Plc CRBP Corbus Pharmaceuticals DMAC DiaMedica Therapeutics DVAX Dynavax Technologies GKOS Glaukos Corp GWPH GW Pharmaceuticals plc HEPA Hepion Pharmaceuticals OCUL Ocular Therapeutix OMER Omeros ONCE Spark Therapeutics UBX Unity Biotechnology ZYNE Zynerba Pharmaceuticals GBT Global Blood Therapeutics ICPT Intercept Pharmaceuticals ALDX Aldeyra The ARCT Arcturus Therapeutics Holdings ATAI ATAI Life Sciences BV PTE Polarityte CLNN Clene MNMD Mind Medicine  AUPH Aurinia Pharmaceuticals BLCM Bellicum Pharmaceuticals BRTX BioRestorative Therapies CYBN Cybin  DMTTF Small Pharma FOLD Amicus Therapeutics GHRS GH Research PLC GLMD Galmed Pharmaceuticals Ltd MNPR Monopar Therapeutics QURE Uniqure NV UNCY Unicycive Therapeutics KTTA Pasithea Therapeutics Corp COYA Coya Therapeutics, Common Stock BTAI BioXcel Therapeutics DRRX Durect FBRX Forte Biosciences LUMO Lumos Pharma MESO Mesoblast Ltd PTI Proteostasis Therapeutics SBBP Strongbridge Biopharma plc SAVA Cassava Sciences AER AerCap Holdings NV CNAT Conatus Pharmaceuticals GBTG Global Business Travel Group INMB INmune Bio KRYS Krystal Biotech

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 16-Oct-2017

$20

$15.71 (366.20%)

$20

13 days ago
(19-Mar-2026)

0/15 (0%)

$15.46 (340.53%)

Buy Since 29-Apr-2025

$19

$14.71 (342.89%)

$20

4 months 20 days ago
(12-Nov-2025)

0/3 (0%)

$14.06 (284.62%)

Buy Since 02-Jun-2025

$20

$15.71 (366.20%)

$19

7 months 17 days ago
(15-Aug-2025)

0/2 (0%)

$12.87 (180.50%)

Buy Since 30-May-2024

$20

$15.55 (349.44%)

$21

10 months 16 days ago
(16-May-2025)

0/2 (0%)

$13.9 (227.87%)

Buy Since 19-Feb-2025

$15

$10.71 (249.65%)

$15

1 years 8 days ago
(24-Mar-2025)

0/2 (0%)

$9.88 (192.97%)

Show more analysts

Please expand the browser size to see the chart

Which stock is Elemer Piros is most bullish on?

Potential upside of $56.61 has been obtained for UNCY (UNICYCIVE THERAPEUTICS)

Which stock is Elemer Piros is most reserved on?

Potential downside of $6.32 has been obtained for SAVA (CASSAVA SCIENCES)

What Year was the first public recommendation made by Elemer Piros?

On 2015

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?